Reversal of Advice for Breast Cancer Patients Experiencing Severe Menopausal Symptoms

Female patients should have the right to receive post-menopausal hormone therapy.

Menopausal Symptoms

I waited to announce the emerging research regarding the safety of post-menopausal hormone replacement therapy for breast cancer patients suffering from severe menopausal symptoms until the research finally supported my belief that women have the right to receive the treatment that they need if they accept the risks of that treatment.

The past year of research (2024-2025) has produced a significant amount of research demonstrating the health risks associated from not taking hormone replacement therapy, as well as the safety of using testosterone after breast cancer and the limited risks of hormone replacement therapy following breast cancer.

I have practiced women’s medicine for over 40 years, and I believe that female patients should have the right to receive post-menopausal hormone therapy if they understand and accept the associated risks and benefits, as long as it is administered safely.

Let me pause here to discuss how doctors ethically make decisions about treatment. First, the aim of medical treatment is to improve health and longevity while alleviating symptoms. It is a doctor’s responsibility to evaluate, treat, and advise patients on the best course of therapy based on their medical training, practical experience, and the latest research. However, the third factor is often overlooked when advising patients about hormone replacement therapy after breast cancer. Doctors determine the best course of treatment by using this information and weighing the benefits of a treatment against its risks. We are trained to provide this information to patients to facilitate informed decision-making with the patient, not for the patient. This process requires time that doctors no longer have. Ah, and therein lies the problem.

Doctors are trained to follow research related to the diseases and conditions they treat and to integrate that research into their practice. The basic decision-making process involves weighing the benefits of treatment (or no treatment) against the associated risks. When the benefits of a treatment outweigh its risks, it is recommended to the patient. “Recommended” means the doctor, based on current knowledge, believes it to be safer and more effective for the patient’s health to pursue a specific treatment. However, this does not imply that the patient must follow the doctor’s advice. A patient is autonomous and can assess the risks and benefits once informed, allowing them to refuse a treatment or request one that falls outside current medical guidelines. Doctors do not have to embark on a treatment they do not believe is beneficial or safe. Doctors have autonomy as well!

Doctors in mainstream medicine adhere to “medical guidelines” established by our specialties, which represent the minimum level of care expected from a physician. However, these guidelines are often decades behind current research, meaning that the risks and benefits communicated to a patient may be outdated. A legal requirement known as informed consent mandates that a doctor inform the patient or include this information in a consent form that the patient reads and signs, detailing the procedure or treatment. If the treatment is newer than the guidelines, it is categorized as “off-label.” It is essential for the doctor to inform the patient that the treatment does not conform to current guidelines, and the patient must acknowledge the known risks associated with the treatment.

At BioBalance Health®, we often find ourselves ahead of the guidelines, and my experience indicates it may take up to 20 years for the guidelines to catch up with us. Much of our treatment is considered off-label because it is current and ahead of the guidelines. It is superior to other treatments and remains safe, but risks are inherent in every treatment!

Now, let’s return to breast cancer and the roles of estradiol, testosterone, and progesterone replacement. Here are the facts about breast cancer:

• Most breast cancer patients are post-menopausal, and have symptoms of menopause
• Not all types of breast cancer are stimulated by estradiol or progesterone, and therefore for these cancers hormone replacement therapy is safe.
• Breast Cancer patients with negative nodes who have had a bilateral mastectomy are candidates for hormone replacement therapy after their treatment.
• The risks of estrogen replacement for ER+ breast cancer patients may promote the growth of cancer cells, while testosterone replacement lowers the risk of recurrence and alleviates certain menopausal symptoms.
• When testosterone is combined with estradiol, the risk of developing breast cancer in all women is reduced.
• Testosterone enhances the quantity and activity of cancer-fighting T-killer and T-helper white blood cells.
• All breast cancer patients can manage menopause symptoms using testosterone pellet therapy and vaginal estrogen without an increased risk of recurrence.

Do you remember when I mentioned that the risks of treatment should be balanced with the benefits of that same treatment?

Recently, numerous research articles have outlined the benefits of estradiol treatment, which I included in my 2017 book, “The Secret Female Hormone: How Testosterone Replacement Can Change Your Life.” In early 2025, the safety of taking estradiol for menopausal women confirmed the less publicized research that had come before. The Journal of Endocrinology and Metabolism reported that women who underwent estradiol replacement after the age of 60 live 20% longer than those who do not take hormone replacement therapy. This challenges the guideline that advises OB-GYNs to discontinue hormone replacement therapy before the age of 60.

The Benefits of Estrogen replacement after menopause, based on multiple research studies over the last 20 years is as follows:

• ERT alleviates symptoms such as dry vagina, painful intercourse, insomnia, hot flashes, and night sweats.
• Estrogen replacement prevents and treats osteoporosis in women.
• Testosterone replacement in women with osteoporosis can reverse the process of bone loss, bringing bone back to normal strength and decreasing fracture risk.
• Non-oral Testosterone and Estradiol can prevent arteriosclerotic heart disease.
• ERT and HRT decreases the risk of diabetes with aging.
• Estradiol replacement during the first decade after menopause can delay the onset of Alzheimer’s disease and dementia by ten years. If you are genetically predisposed to developing Alzheimer’s or dementia by age 80, E2 replacement may postpone this onset until you turn 90.
• Testosterone replacement in the first 10 years after menopause postpones the onset of Alzheimer’s disease and dementia for an additional ten years.
• Testosterone boosts immune function in both sexes and diminishes the onset and severity of infectious diseases.
• Aging causes cognitive decline, marked by challenges in memory and thinking, and menopause speeds up this process. Testosterone and estradiol replacement therapies may aid in reversing this decline.
• Muscle mass decreases after menopause due to a decline in testosterone but replacing testosterone with bio-identical pellets restores muscle mass to premenopausal levels.

The latest medical article that inspired me to create this podcast was published in the journal Menopause, which discussed the challenges many women face after breast cancer treatment without hormone replacement for their severe menopausal symptoms. Here are the quotes I think you should hear: (MHT = Menopause Hormone Therapy)

“Among 226 breast cancer survivors.. the menopause symptom burden was high and

women’s experience of menopause-related breast cancer after-care was poor. Few women felt actively involved in menopause treatment decisions.

 The NICE breast cancer guideline (NG101) states that women with a history of

breast cancer can be offered MHT in “exceptional” circumstances if other treatments have failed (off-label use). However, NICE does not define what “exceptional” circumstances are or who gets to decide.

Up to 50% of breast cancer survivors, especially those with debilitating menopausal symptoms, may choose to accept a small increase in risk in exchange for an

improved quality of life and/or to mitigate future health risks associated with chronic estrogen deficiency.  “Allowing”. women to have MHT only in “exceptional” circumstance undermines patient autonomy and limits a clinician’s ability to integrate clinical knowledge and judgment with the best currently available evidence (which is decades behind clinical guidelines). Clinicians have a legal and ethical responsibility to patients to make informed treatment choices.

If you have had breast cancer and are experiencing symptoms you no longer want to endure, my advice is to find a doctor with whom you can make an informed decision based on the latest research. It’s important to understand and accept the risks and to sign a High-Risk Consent for HRT. 

If you aren’t that brave, then seek a physician who will prescribe testosterone pellets along with vaginal estradiol to alleviate some of your post-menopausal symptoms. Life is too short to follow guidelines that are 20 years out of date when you are suffering.